Business Context and Reporting Period
Company: Hydrofarm Holdings Group, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 15, 2025
Reporting Period: Specific event date of April 15, 2025.
Business Context: The filing discloses an amendment to the employment agreement of the Chief Executive Officer, B. John Lindeman, regarding compensation upon termination and change of control.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation terms.
Material Changes
The material change reported is the execution of an amendment to the CEO's Offer Letter dated February 26, 2020. The amendment revises severance and equity acceleration terms as follows:
- Standard Termination (Without Cause):
- Cash Severance: The greater of $237,500 or six (6) months of base salary.
- Equity Acceleration: Twelve (12) months of additional vesting on outstanding awards.
- Termination Within 18 Months of Change of Control:
- Cash Severance: The greater of $500,000 or twelve (12) months of base salary.
- Health Benefits: Payment of COBRA premiums for twelve (12) months.
- Equity Acceleration: Twelve (12) months of additional vesting on outstanding awards.
Guidance, Outlook, and Risks
Management Commentary: The filing provides no forward-looking guidance, outlook, or general management commentary regarding business operations.
Risks and Contingencies: The filing highlights the financial contingency of potential executive severance payments, specifically increasing the potential payout in the event of a Change of Control. The full terms are qualified by reference to the attached Exhibit 10.1.
Investor Verification Checklist
- Verify the current base salary of CEO B. John Lindeman to calculate the exact potential severance amounts (6 months vs. $237,500; 12 months vs. $500,000).
- Review the full text of the Offer Letter Amendment (Exhibit 10.1) for specific definitions of "Change of Control" and "termination without cause."
- Assess the impact of the 12-month equity acceleration on the company's dilution and compensation expense in the event of a transaction.
- Confirm if this amendment aligns with the company's 2020 Employee, Director and Consultant Equity Incentive Plan.